This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2007 Jan;3(1):12-3.

doi: 10.1038/ncpneph0363.

Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism

David A Bushinsky¹

Affiliations

PMID: 17183255
DOI: 10.1038/ncpneph0363

Comment

Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism

David A Bushinsky. Nat Clin Pract Nephrol. 2007 Jan.

. 2007 Jan;3(1):12-3.

doi: 10.1038/ncpneph0363.

Author

David A Bushinsky¹

Affiliation

¹ Nephrology Division, University of Rochester School of Medicine, Rochester, NY 14642, USA. david_bushinsky@urmc.rochester.edu

PMID: 17183255
DOI: 10.1038/ncpneph0363

No abstract available

PubMed Disclaimer

Comment in

Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism.
Mansour J, Shahapuni I, Mailliez S, Aghai R, Fournier A. Mansour J, et al. Nat Clin Pract Nephrol. 2007 Apr;3(4):E2; discussion E3. doi: 10.1038/ncpneph0442. Nat Clin Pract Nephrol. 2007. PMID: 17389886 Review. No abstract available.

Comment on

Initial dosing of paricalcitol based on PTH levels in hemodialysis patients with secondary hyperparathyroidism.
Mitsopoulos E, Zanos S, Ginikopoulou E, Kyriklidou P, Meimaridou D, Sakellariou G. Mitsopoulos E, et al. Am J Kidney Dis. 2006 Jul;48(1):114-21. doi: 10.1053/j.ajkd.2006.04.060. Am J Kidney Dis. 2006. PMID: 16797393 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.